| Prexasertib studied in …STUDIED_INderived19 of 19show fewer |
|---|
| → studied in | NCT05548296Phase 2 · recruiting A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma · 19 trials list this drug (2 active) | — | — | Endometrial Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06597565Phase 2 · recruiting A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC · 19 trials list this drug (2 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04095221Phase 1/Phase 2 · completed A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma · 19 trials list this drug (2 active) | — | — | Desmoplastic Small Round Cell Tumor,Rhabdomyosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04023669Phase 1 · completed Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors · 19 trials list this drug (2 active) | — | — | Central Nervous System Neoplasm,Malignant Central Nervous System Neoplasm,Medulloblastoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02808650Phase 1 · completed Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors · 19 trials list this drug (2 active) | — | — | Childhood Solid Neoplasm,Malignant Solid Neoplasm,Primary Central Nervous System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02649764Phase 1 · completed Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome · 19 trials list this drug (2 active) | — | — | Acute Myeloid Leukemia,Chronic Myelomonocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02873975Phase 2 · completed A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency · 19 trials list this drug (2 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02203513Phase 2 · terminated A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer · 19 trials list this drug (2 active) | — | — | Malignant Breast Neoplasm,Malignant Ovarian Neoplasm,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03414047Phase 2 · completed A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer · 19 trials list this drug (2 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03057145Phase 1 · completed Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors · 19 trials list this drug (2 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03495323Phase 1 · completed A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors · 19 trials list this drug (2 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02124148Phase 1 · completed A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer · 19 trials list this drug (2 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02735980Phase 2 · completed A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer · 19 trials list this drug (2 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02778126Phase 1 · completed A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer · 19 trials list this drug (2 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03735446Phase 1 · terminated Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial · 19 trials list this drug (2 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02555644Phase 1 · completed A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer · 19 trials list this drug (2 active) | — | — | Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02860780Phase 1 · completed A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer · 19 trials list this drug (2 active) | — | — | Malignant Neoplasm,Lung Non-Small Cell Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02514603Phase 1 · completed A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers · 19 trials list this drug (2 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01115790Phase 1 · completed A Phase 1 Study in Participants With Advanced Cancer · 19 trials list this drug (2 active) | — | — | Malignant Neoplasm,Carcinoma,Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |